典型文献
Jinbo Bio-Pharmaceutical restarted IPO in Beijing Stock Exchange
文献摘要：
On November 23rd, 2022, Jinbo Bio-Pharmaceutical released announced that it already submitted the application and relevant materials to Beijing Stock Exchange and it resumed the review now. In December, 2021, it tried to get listed in Beijing Stock Exchange. In September 2022, it stopped its listing review due to its need to update the financial materials quoted in prospectus. In the first three quarters in 2022, it achieved a revenue of 251 million yuan, an increase of 70.27％ year-on-year, gaining a net profit of 70.2378 million yuan, an increase of 97.78％ year on year. According to the public profile, it was founded in 2008 and it focused on the research and development, production and sales of various medical devices and functional skin care products with re-combinant collagen products and anti-HPV biological protein products as the core.
文献关键词：
中图分类号：
作者姓名：
作者机构：
文献出处：
引用格式：
[1]-.Jinbo Bio-Pharmaceutical restarted IPO in Beijing Stock Exchange)[J].日用化学品科学（英文）,2022(04):5
A类：
Jinbo,prospectus,combinant
B类：
Bio,Pharmaceutical,restarted,IPO,Beijing,Stock,Exchange,On,November,23rd,released,announced,that,already,submitted,application,relevant,materials,resumed,review,now,In,December,tried,get,listed,nbsp,September,stopped,its,listing,due,need,update,financial,quoted,first,three,quarters,achieved,revenue,million,yuan,increase,year,gaining,net,profit,According,public,profile,was,founded,focused,research,development,production,sales,various,medical,devices,functional,skin,care,products,collagen,anti,HPV,biological,protein,core
AB值：
0.592006
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
